Long-Term Effectiveness of Galcanezumab in the Prevention of Migraine: An Italian Retrospective Analysis (REALITY)-Reference-Cited by-同舟云学术

Long-Term Effectiveness of Galcanezumab in the Prevention of Migraine: An Italian Retrospective Analysis (REALITY)

Published:2024-02-08 Issue:2 Volume:13 Page:415-435
ISSN:2193-8253
Container-title:Neurology and Therapy
language:en
Short-container-title:Neurol Ther

Author:

Vernieri Fabrizio^ORCID,Iannone Luigi Francesco,Guerzoni Simona,Russo Antonio,Barbanti Piero,Sances Grazia,Cevoli Sabina,Rao Renata,Lovati Carlo,Ambrosini Anna,Buzzoni Carlotta,Battisti Federico,Vatteone Laura,King Steffy Martin Luther,Torelli Federico

Funder

Eli Lilly and Company

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40120-024-00582-0.pdf

Reference28 articles.

1. Woldeamanuel YW, Cowan RP. Migraine affects 1 in 10 people worldwide featuring recent rise: a systematic review and meta-analysis of community-based studies involving 6 million participants. J Neurol Sci. 2017;372:307–15. https://doi.org/10.1016/j.jns.2016.11.071.

2. Aguilar-Shea AL, Membrilla Md JA, Diaz-de-Teran J. Migraine review for general practice. Aten Primaria. 2022;54(2):102208. https://doi.org/10.1016/j.aprim.2021.102208.

3. Doane MJ, Vo P, Bilitou A et al. Economic impact of migraine in the EU5: a matched analysis of the NHWS 2017 data on work productivity and healthcare resource use. Abstract no. [MTIS2018-083]. In: MTIS 2018 abstracts. Cephalalgia. 2018;38(1S). https://journals.sagepub.com/doi/pdf/10.1177/0333102418789865.

4. Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021;17(8):501–14. https://doi.org/10.1038/s41582-021-00509-5.

5. Deen M, Correnti E, Kamm K, et al. Blocking CGRP in migraine patients—a review of pros and cons. J Headache Pain. 2017;18:96. https://doi.org/10.1186/s10194-017-0807-1.